ArticleNature chemical biology2018
Inhibiting mitochondrial phosphate transport as an unexploited antifungal strategy.
Article in Nature chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Mitochondrial copper stabilizes lipoylated TCA cycle proteins to sustain metabolism and proliferation.bioRxiv : the preprint server for biology · 2026Article
- Inhibiting Mrt4-rRNA interaction with fumaramidmycin-based derivatives as an antifungal strategy.Nature communications · 2026Article
- A mitochondria-targeted aggregation-induced emission photosensitizer for eradicationSmart molecules : open access · 2025Article
- Uncovering the role of mitochondrial genome in pathogenicity and drug resistance in pathogenic fungi.Frontiers in cellular and infection microbiology · 2025Review
- The progress and future of the treatment of Candida albicans infections based on nanotechnology.Journal of nanobiotechnology · 2024Review
- Cucurbit[8]uril-based supramolecular theranostics.Journal of nanobiotechnology · 2024Review
- Redefining pleiotropic drug resistance in a pathogenic yeast: Pdr1 functions as a sensor of cellular stresses inmSphere · 2023Article
- Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review.Antimicrobial agents and chemotherapy · 2023Review
- Bioengineered materials with selective antimicrobial toxicity in biomedicine.Military Medical Research · 2023Review
- Aggregation-induced emission biomaterials for anti-pathogen medical applications: detecting, imaging and killing.Regenerative biomaterials · 2023Review
- Stereoisomeric engineering of aggregation-induced emission photosensitizers towards fungal killing.Nature communications · 2022Article
- Disruption of Iron Homeostasis and Mitochondrial Metabolism Are Promising Targets to Inhibit Candida auris.Microbiology spectrum · 2022Article
- The phosphate language of fungi.Trends in microbiology · 2022Review
- Selective Antifungal Activity and Fungal Biofilm Inhibition of Tryptophan Center Symmetrical Short Peptide.International journal of molecular sciences · 2021Article
- Phosphate in Virulence ofJournal of fungi (Basel, Switzerland) · 2020Review
- Inhibiting Fungal Echinocandin Resistance by Small-Molecule Disruption of Geranylgeranyltransferase Type I Activity.Antimicrobial agents and chemotherapy · 2020Article
- Novel mitochondrial complex I-inhibiting peptides restrain NADH dehydrogenase activity.Scientific reports · 2019Article
- Efflux pump-mediated resistance to antifungal compounds can be prevented by conjugation with triphenylphosphonium cation.Nature communications · 2018Article
- Potential targets for the development of new antifungal drugs.The Journal of antibiotics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
The development of effective antifungal therapeutics remains a formidable challenge because of the close evolutionary relationship between humans and fungi. Mitochondrial function may present an exploitable vulnerability because of its differential utilization in fungi and its pivotal roles in fungal morphogenesis, virulence, and drug resistance already demonstrated by others. We now report mechanistic characterization of ML316, a thiohydantoin that kills drug-resistant Candida species at nanomolar concentrations through fungal-selective inhibition of the mitochondrial phosphate carrier Mir1. Using genetic, biochemical, and metabolomic approaches, we established ML316 as the first Mir1 inhibitor. Inhibition of Mir1 by ML316 in respiring yeast diminished mitochondrial oxygen consumption, resulting in an unusual metabolic catastrophe marked by citrate accumulation and death. In a mouse model of azole-resistant oropharyngeal candidiasis, ML316 reduced fungal burden and enhanced azole activity. Targeting Mir1 could provide a new, much-needed therapeutic strategy to address the rapidly rising burden of drug-resistant fungal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.